{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T04:18:20Z","timestamp":1772770700035,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,30]]},"DOI":"10.7759\/cureus.46282","type":"journal-article","created":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T22:13:51Z","timestamp":1696112031000},"source":"Crossref","is-referenced-by-count":1,"title":["Reassessing the Safety of Pill-in-the-Pocket Propafenone"],"prefix":"10.7759","author":[{"given":"Andrew G","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majid","family":"Yavari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rand","family":"Sabanci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esosa","family":"Ukponmwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatima","family":"Ali-Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1988.tb11737.x","article-title":"Electrophysiological mechanism for the antiarrhythmic action of propafenone: a comparison with mexiletine","volume":"95","author":"Amerini S","year":"1988","unstructured":"Amerini S, Bernabei R, Carbonin P, Cerbai E, Mugelli A, Pahor M. Electrophysiological mechanism for the antiarrhythmic action of propafenone: a comparison with mexiletine. Br J Pharmacol. 1988, 95:1039-46. 10.1111\/j.1476-5381.1988.tb11737.x","journal-title":"Br J Pharmacol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1995.tb01225.x","article-title":"Propafenone in a usual dose produces severe side-effects: the impact of genetically determined metabolic status on drug therapy","volume":"238","author":"M\u00f6rike K","year":"1995","unstructured":"M\u00f6rike K, Magadum S, Mettang T, Griese EU, Machleidt C, Kuhlmann U. Propafenone in a usual dose produces severe side-effects: the impact of genetically determined metabolic status on drug therapy. J Intern Med. 1995, 238:469-72. 10.1111\/j.1365-2796.1995.tb01225.x","journal-title":"J Intern Med"},{"key":"ref3","article-title":"The \"pill-in-the-pocket\" approach to atrial fibrillation","volume":"352","author":"Konety SH","year":"2005","unstructured":"Konety SH, Olshansky B. The \"pill-in-the-pocket\" approach to atrial fibrillation. N Engl J Med. 2005, 352:1150-1; author reply 1150-1.","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041233","article-title":"Outpatient treatment of recent-onset atrial fibrillation with the \"pill-in-the-pocket\" approach","volume":"351","author":"Alboni P","year":"2004","unstructured":"Alboni P, Botto GL, Baldi N, et al.. Outpatient treatment of recent-onset atrial fibrillation with the \"pill-in-the-pocket\" approach. N Engl J Med. 2004, 351:2384-91. 10.1056\/NEJMoa041233","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000040","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society","volume":"130","author":"January CT","year":"2014","unstructured":"January CT, Wann LS, Alpert JS, et al.. 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014, 130:2071-104. 10.1161\/CIR.0000000000000040","journal-title":"Circulation"},{"key":"ref6","article-title":"Proarrhythmia induced by propafenone: what is the mechanism?","volume":"10","author":"Femenia F","year":"2010","unstructured":"Femenia F, Palazzolo J, Arce M, Arrieta M. Proarrhythmia induced by propafenone: what is the mechanism?. Indian Pacing Electrophysiol J. 2010, 10:278-80.","journal-title":"Indian Pacing Electrophysiol J"},{"key":"ref7","article-title":"How do atrial-selective drugs differ from antiarrhythmic drugs currently used in the treatment of atrial fibrillation?","volume":"1","author":"Burashnikov A","year":"2008","unstructured":"Burashnikov A, Antzelevitch C. How do atrial-selective drugs differ from antiarrhythmic drugs currently used in the treatment of atrial fibrillation?. J Atr Fibrillation. 2008, 1:98-107.","journal-title":"J Atr Fibrillation"},{"key":"ref8","article-title":"Propafenone therapy and CYP2D6 genotype","author":"Dean L","year":"2017","unstructured":"Dean L. Propafenone therapy and CYP2D6 genotype. Medical Genetics Summaries. Pratt VM, Scott SA, Pirmohamed M, et al. (ed): National Center for Biotechnology Information (US), Bethesda (MD); 2017."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.75.4.785","article-title":"Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences","volume":"75","author":"Siddoway LA","year":"1987","unstructured":"Siddoway LA, Thompson KA, McAllister CB, Wang T, Wilkinson GR, Roden DM, Woosley RL. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation. 1987, 75:785-91. 10.1161\/01.cir.75.4.785","journal-title":"Circulation"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116441","article-title":"Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans","volume":"91","author":"Evans WE","year":"1993","unstructured":"Evans WE, Relling MV, Rahman A, McLeod HL, Scott EP, Lin JS. Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans. J Clin Invest. 1993, 91:2150-4. 10.1172\/JCI116441","journal-title":"J Clin Invest"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2116\/analsci.20.1307","article-title":"A rapid HPLC assay for the simultaneous determination of propafenone and its major metabolites in human serum","volume":"20","author":"Afshar M","year":"2004","unstructured":"Afshar M, Rouini M. A rapid HPLC assay for the simultaneous determination of propafenone and its major metabolites in human serum. Anal Sci. 2004, 20:1307-11. 10.2116\/analsci.20.1307","journal-title":"Anal Sci"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2174\/138920008784220664","article-title":"Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4","volume":"9","author":"Zhou SF","year":"2008","unstructured":"Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab. 2008, 9:310-22. 10.2174\/138920008784220664","journal-title":"Curr Drug Metab"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1021\/jm020400s","article-title":"A model for predicting likely sites of CYP3A4-mediated metabolism on drug-like molecules","volume":"46","author":"Singh SB","year":"2003","unstructured":"Singh SB, Shen LQ, Walker MJ, Sheridan RP. A model for predicting likely sites of CYP3A4-mediated metabolism on drug-like molecules. J Med Chem. 2003, 46:1330-6. 10.1021\/jm020400s","journal-title":"J Med Chem"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198212163072505","article-title":"Oxidation phenotype--a major determinant of metoprolol metabolism and response","volume":"307","author":"Lennard MS","year":"1982","unstructured":"Lennard MS, Silas JH, Freestone S, Ramsay LE, Tucker GT, Woods HF. Oxidation phenotype--a major determinant of metoprolol metabolism and response. N Engl J Med. 1982, 307:1558-60. 10.1056\/NEJM198212163072505","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02343.x","article-title":"Diltiazem inhibits human intestinal cytochrome P450 3A (CYP3A) activity in vivo without altering the expression of intestinal mRNA or protein","volume":"59","author":"Pinto AG","year":"2005","unstructured":"Pinto AG, Horlander J, Chalasani N, Hamman M, Asghar A, Kolwankar D, Hall SD. Diltiazem inhibits human intestinal cytochrome P450 3A (CYP3A) activity in vivo without altering the expression of intestinal mRNA or protein. Br J Clin Pharmacol. 2005, 59:440-6. 10.1111\/j.1365-2125.2005.02343.x","journal-title":"Br J Clin Pharmacol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199704000-00007","article-title":"CYP2D6 inhibition in patients treated with sertraline","volume":"17","author":"Sproule BA","year":"1997","unstructured":"Sproule BA, Otton SV, Cheung SW, Zhong XH, Romach MK, Sellers EM. CYP2D6 inhibition in patients treated with sertraline. J Clin Psychopharmacol. 1997, 17:102-6. 10.1097\/00004714-199704000-00007","journal-title":"J Clin Psychopharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/191829-reassessing-the-safety-of-pill-in-the-pocket-propafenone","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:08:45Z","timestamp":1707509325000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/191829-reassessing-the-safety-of-pill-in-the-pocket-propafenone"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,30]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.46282","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,30]]}}}